Home TMU Sitemap FAQ Links
正體中文
Home Ongoing Clinical Trials
Ongoing Clinical Trials

Institution
Principal Investigator
Protocol Title
Keyword
TMU-JIRB No. Protocol Title Institution / Principal Investigator Type of Study Phases of Clinical Trials for Drugs
N202502002 A Phase 3 Multicenter, Randomized, Open-label Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab Versus Standard of Care in the First-line Treatment of Patients With Locoregional Recurrence of Squamous Cell Carcinoma of the Head and Neck (HNSCC) With No Distant Metastases New Medical Device NA
N202502011 A Phase III, Randomised, Double-blind, Placebo-controlled, Event driven Study to Evaluate the Effect of Baxdrostat in Combination with Dapagliflozin Compared with Dapagliflozin Alone on the Risk of Incident Heart Failure and Cardiovascular Death in Participants with Increased Risk of Developing Heart Failure New Drug Phase Ⅰ
N202502013 A Phase III, Randomised, Double-blind, Placebo-controlled, Event driven Study to Evaluate the Effect of Baxdrostat in Combination with Dapagliflozin Compared with Dapagliflozin Alone on the Risk of Incident Heart Failure and Cardiovascular Death in Participants with Increased Risk of Developing Heart Failure New Drug Phase Ⅲ
N202502020 A Phase IIb, Multicentre, Double-blind, Placebo-controlled Dose Range Finding Study to Assess Efficacy and Safety of Tozorakimab in Adult Participants With Uncontrolled Asthma on Medium-to-High Dose Inhaled Corticosteroids (UMBRIEL) New Medical Device NA
N202502021 A Study of Remternetug Versus Placebo in Early Alzheimer’s Disease Participants at Risk for Cognitive and Functional Decline New Drug Phase Ⅰ
N202502025 Evaluate the efficacy and safety of "EXOLENS daily disposable soft contact lenses" in relieving myopic patients with dry eye symptoms New Medical Device NA
N202502033 Clinical Study to Evaluate the Efficacy of the Lite-Med LM-IASO Device for the Treatment of Urge Urinary Incontinence (UUI) in Women New Medical Device NA / Phase Ⅲ
N202502038 A Phase 3, randomized, double-blind, placebo-controlled, parallel-group study to investigate the efficacy and safety of dupilumab for the treatment of pruritus of Lichen Simplex Chronicus (LSC) in adults Bioavailability / Bioequivalence (BA/BE) NA
1 2 3 4 5 6 7 8 9 10 31 32 / 32

TOP